-
1
-
-
0037258487
-
Epidemiology of reflux disease and CLE in East Asia
-
Hongo M, Shoji T. Epidemiology of reflux disease and CLE in East Asia. J Gastroenterol 2003;38 (Suppl):25-30. (Pubitemid 36442881)
-
(2003)
Journal of Gastroenterology
, vol.38
, Issue.SUPPL. 15
, pp. 25-30
-
-
Hongo, M.1
Shoji, T.2
-
2
-
-
0037299893
-
Clinical characteristics of Japanese reflux esophagitis patients as determined by Los Angeles classification
-
DOI 10.1046/j.1440-1746.2003.02932.x
-
Inamori M, Togawa J, Nagase H et al. Clinical characteristics of Japanese reflux esophagitis patients as determined by Los Angeles classification. J Gastroenterol Hepatol 2003;18:172-6. (Pubitemid 36349864)
-
(2003)
Journal of Gastroenterology and Hepatology
, vol.18
, Issue.2
, pp. 172-176
-
-
Inamori, M.1
Togawa, J.-I.2
Nagase, H.3
Abe, Y.4
Umezawa, T.5
Nakajima, A.6
Saito, T.7
Ueno, N.8
Tanaka, K.9
Sekihara, H.10
Kaifu, H.11
Tsuboi, H.12
Kayama, H.13
Tominaga, S.14
Nagura, H.15
-
3
-
-
0035102333
-
Role of hiatus hernia and gastric mucosal atrophy in the development of reflux esophagitis in the elderly
-
DOI 10.1046/j.1440-1746.2001.02408.x
-
Amano K, Adachi K, Katsube T et al. Role of hiatus hernia and gastric mucosal atrophy in the development of reflux esophagitis in the elderly. J Gastroenterol Hepatol 2001;16:132-6. (Pubitemid 32226183)
-
(2001)
Journal of Gastroenterology and Hepatology
, vol.16
, Issue.2
, pp. 132-136
-
-
Amano, K.1
Adachi, K.2
Katsube, T.3
Watanabe, M.4
Kinoshita, Y.5
-
4
-
-
0035700390
-
Influence of Helicobacter pylori infection on the prevalence of reflux esophagitis in Japanese patients
-
DOI 10.1046/j.1440-1746.2001.02618.x
-
Fujishiro H, Adachi K, Kawamura ura A et al. Influence of H elicobacter pylori infection on the prevalence of reflux esophagitis in Japanese patients. J Gastroenterol Hepatol 2001;16:1217-21. (Pubitemid 34088267)
-
(2001)
Journal of Gastroenterology and Hepatology
, vol.16
, Issue.11
, pp. 1217-1221
-
-
Fujishiro, H.1
Adachi, K.2
Kawamura, A.3
Katsube, T.4
Ono, M.5
Yuki, M.6
Amano, K.7
Ishihara, S.8
Kinoshita, Y.9
-
5
-
-
0032915278
-
Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease
-
DOI 10.1046/j.1365-2036.1999.00438.x
-
Dekkers CPM, Beker JA, Th jodleifsson B et al. Double-blind, placebocontrolled comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Th er 1999;13:49-57. (Pubitemid 29048056)
-
(1999)
Alimentary Pharmacology and Therapeutics
, vol.13
, Issue.1
, pp. 49-57
-
-
Dekkers, C.P.M.1
Beker, J.A.2
Thjodleifsson, B.3
Gabryelewicz, A.4
Bell, N.E.5
Humphries, T.J.6
-
6
-
-
33746610921
-
Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism
-
DOI 10.1111/j.1440-1746.2006.04190.x
-
Ariizumi K, Ohara S, Koike T et al. Th erapeutic eff ects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism. J Gastroenterol Hepatol 2006;21:1428-34. (Pubitemid 44154712)
-
(2006)
Journal of Gastroenterology and Hepatology
, vol.21
, Issue.9
, pp. 1428-1434
-
-
Ariizumi, K.1
Ohara, S.2
Koike, T.3
Inomata, Y.4
Iijima, K.5
Sekine, H.6
Noguchi, M.7
Sugiyama, K.8
Eda, Y.9
Kayaba, S.10
Kawamura, M.11
Shimosegawa, T.12
-
7
-
-
0036127851
-
Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis
-
DOI 10.1016/S0002-9270(01)04094-1, PII S0002927001040941
-
Castell DO, Kahrilas PJ, Ritchter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-83. (Pubitemid 34245883)
-
(2002)
American Journal of Gastroenterology
, vol.97
, Issue.3
, pp. 575-583
-
-
Castell, D.O.1
Kahrilas, P.J.2
Richter, J.E.3
Vakil, N.B.4
Johnson, D.A.5
Zuckerman, S.6
Skammer, W.7
Levine, J.G.8
-
8
-
-
0033785204
-
Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial
-
Kahrilas PJ, Falk GW, Johnson DA et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Th er 2000;14:1249-58.
-
(2000)
Aliment Pharmacol Th Er
, vol.14
, pp. 1249-1258
-
-
Kahrilas, P.J.1
Falk, G.W.2
Johnson, D.A.3
-
9
-
-
39049183768
-
Treatment of proton pump inhibitor - Resistant patients with gastroesophageal reflux disease
-
Kinoshita Y, Kazumori H, Ishihara S. Treatment of proton pump inhibitor - resistant patients with gastroesophageal reflux disease. J Gastroenterol 2006;41:286-7.
-
(2006)
J Gastroenterol
, vol.41
, pp. 286-287
-
-
Kinoshita, Y.1
Kazumori, H.2
Ishihara, S.3
-
10
-
-
22844451154
-
Systematic review: Proton-pump inhibitor failure in gastro-oesophageal reflux disease - Where next?
-
DOI 10.1111/j.1365-2036.2005.02531.x
-
Fass R, Shapiro M, Dekel R et al. Systematic review: systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease- where next? Aliment Pharmacol Th er 2005;22:79-94. (Pubitemid 41039696)
-
(2005)
Alimentary Pharmacology and Therapeutics
, vol.22
, Issue.2
, pp. 79-94
-
-
Fass, R.1
Shapiro, M.2
Dekel, R.3
Sewell, J.4
-
11
-
-
58849095408
-
Management of heartburn not responding to proton pump inhibitors
-
Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009;58:295-309.
-
(2009)
Gut
, vol.58
, pp. 295-309
-
-
Fass, R.1
Sifrim, D.2
-
12
-
-
0027858321
-
Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases
-
Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol 1993;28 (Suppl 199):18-21. (Pubitemid 24084823)
-
(1993)
Scandinavian Journal of Gastroenterology, Supplement
, vol.28
, Issue.199
, pp. 18-21
-
-
Dimenas, E.1
-
13
-
-
33746709974
-
Th e Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus
-
Vakil N, van Zanten S, Kahrilas P et al. Th e Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20.
-
(2006)
Am J Gastroenterol
, vol.101
, pp. 1900-1920
-
-
Vakil, N.1
Van Zanten, S.2
Kahrilas, P.3
-
14
-
-
0032998835
-
An evidence-based appraisal of reflux disease management - The Genval Workshop Report
-
Dent J, Brun J, Fendrick AM et al. An evidence-based appraisal of reflux disease management-the Genval Workshop Report. Gut 1999;44 (Suppl 2):S1-S16. (Pubitemid 29151973)
-
(1999)
Gut
, vol.44
, Issue.SUPPL. 2
-
-
Dent, J.1
Brun, J.2
Fendrick, A.M.3
Fennerty, M.B.4
Janssens, J.5
Kahrilas, P.J.6
Lauritsen, K.7
Reynolds, J.C.8
Shaw, M.9
Talley, N.J.10
-
15
-
-
13744261420
-
Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease
-
DOI 10.1111/j.1572-0241.2005.41217.x
-
DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200. (Pubitemid 41623288)
-
(2005)
American Journal of Gastroenterology
, vol.100
, Issue.1
, pp. 190-200
-
-
DeVault, K.R.1
Castell, D.O.2
-
16
-
-
9144242617
-
Symptom relief in patients with reflux esophagitis: Comparative study of omeprazole, lansoprazole, and rabeprazole
-
DOI 10.1046/j.1440-1746.2003.03190.x
-
Adachi K, Hashimoto T, Hamamoto N et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol 2003;18:1392-8. (Pubitemid 38045853)
-
(2003)
Journal of Gastroenterology and Hepatology
, vol.18
, Issue.12
, pp. 1392-1398
-
-
Adachi, K.1
Hashimoto, T.2
Hamamoto, N.3
Hirakawa, K.4
Niigaki, M.5
Miyake, T.6
Taniura, H.7
Ono, M.8
Kaji, T.9
Suetsugu, H.10
Yagi, J.11
Komazawa, Y.12
Mihara, T.13
Katsube, T.14
Fujishiro, H.15
Shizuku, T.16
Hattori, S.17
Yamamoto, S.18
Kinoshita, Y.19
-
17
-
-
0036188029
-
Onset of symptom relief with rabeprazole: A community-based, open-label assessment of patients with erosive oesophagitis
-
DOI 10.1046/j.1365-2036.2002.01181.x
-
Robinson M, Fitzgerald S, Hegedus R et al. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Th er 2002;16:445-54. (Pubitemid 34214523)
-
(2002)
Alimentary Pharmacology and Therapeutics
, vol.16
, Issue.3
, pp. 445-454
-
-
Robinson, M.1
Fitzgerald, S.2
Hegedus, R.3
Murthy, A.4
Jokubaitis, L.5
-
18
-
-
0036191747
-
A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease
-
DOI 10.1046/j.1365-2036.2002.01207.x
-
Holtmann G, Bytzer P, Metz M et al. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Th er 2002;16 : 479-85. (Pubitemid 34214527)
-
(2002)
Alimentary Pharmacology and Therapeutics
, vol.16
, Issue.3
, pp. 479-485
-
-
Holtmann, G.1
Bytzer, P.2
Metz, M.3
Loeffler, V.4
Blum, A.L.5
-
19
-
-
9944234997
-
Review article: Relief of symptoms in gastric acid-related diseases - Correlation with acid suppression in rabeprazole treatment
-
Miner P. Relief of symptoms in gastric acid-related diseases- correlation with acid suppression in rabeprazole treatment. Aliment Pharmacol Th er 2004;20 (Suppl. 6):20-9. (Pubitemid 39593284)
-
(2004)
Alimentary Pharmacology and Therapeutics, Supplement
, vol.20
, Issue.6
, pp. 20-29
-
-
Miner, P.1
-
20
-
-
1642574277
-
Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression
-
DOI 10.1046/j.1365-2036.2003.01821.x
-
Shimatani T, Inoue M, Kuroiwa T et al. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Th er 2004;19:113-22. (Pubitemid 38125644)
-
(2004)
Alimentary Pharmacology and Therapeutics
, vol.19
, Issue.1
, pp. 113-122
-
-
Shimatani, T.1
Inoue, M.2
Kuroiwa, T.3
Horikawa, Y.4
-
21
-
-
10744225156
-
Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicopbacter pylori-negative subject: Effects of different regimens
-
DOI 10.1007/s00535-003-1157-0
-
Adachi K, Komazawa Y, Fujishiro H et al. Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: eff ects of diff erent regimens. J Gastroenterol 2003;38:830-5. (Pubitemid 37322028)
-
(2003)
Journal of Gastroenterology
, vol.38
, Issue.9
, pp. 830-835
-
-
Adachi, K.1
Komazawa, Y.2
Fujishiro, H.3
Mihara, T.4
Ono, M.5
Yuki, M.6
Kawamura, A.7
Karim, R.M.A.8
Amano, Y.9
Kinoshita, Y.10
-
22
-
-
33748921737
-
Acid-suppressive effects of rabeprazole: Comparing 10 mg and 20 mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers
-
DOI 10.1016/j.dld.2006.06.002, PII S1590865806002416
-
Shimatani T, Moriwaki M, Xu J et al. Acid-suppressive eff ects of rabeprazole: comparing 10 and 20 mg twice daily in Japanese Helicobacter pylori-negative and-positive CYP2C19 extensive metabolisers. Dig Liver Dis 2006;38:802-8. (Pubitemid 44430926)
-
(2006)
Digestive and Liver Disease
, vol.38
, Issue.11
, pp. 802-808
-
-
Shimatani, T.1
Moriwaki, M.2
Xu, J.3
Tazuma, S.4
Inoue, M.5
-
23
-
-
0034518996
-
Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastro-oesophageal reflux disease
-
DOI 10.1080/003655200453566
-
Delchier JC, Cohen G, Humphries TJ. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastro-oesophageal reflux disease. Scand J Gastroenterol 2000;35:1245-50. (Pubitemid 32051636)
-
(2000)
Scandinavian Journal of Gastroenterology
, vol.35
, Issue.12
, pp. 1245-1250
-
-
Delchier, J.-C.1
Cohen, G.2
Humphries, T.J.3
-
24
-
-
33750466912
-
A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: A randomized three-way crossover study
-
DOI 10.1111/j.1365-2036.2006.03140.x
-
Miki M, Adachi K, Azumi T et al. A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study. Aliment Pharmacol Th er 2006;24:1445-51. (Pubitemid 44657121)
-
(2006)
Alimentary Pharmacology and Therapeutics
, vol.24
, Issue.10
, pp. 1445-1451
-
-
Miki, M.1
Adachi, K.2
Azumi, T.3
Koshino, K.4
Furuta, K.5
Kinoshita, Y.6
-
25
-
-
10344259101
-
Dose this woman have osteoporosis?
-
Amanda DG, Cathleen SCE, Lori B et al. Dose this woman have osteoporosis? JAMA 2004;292:2890-900.
-
(2004)
JAMA
, vol.292
, pp. 2890-2900
-
-
Amanda, D.G.1
Cathleen, S.C.E.2
Lori, B.3
|